Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60243 participants
OBSERVATIONAL
2017-06-09
2019-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Patient With Frequent COPD Exacerbations
NCT07221981
Exacerbations and Their Outcomes International (EXACOS International)
NCT04928417
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01205269
Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD
NCT02330952
Efficacy of DNK333 in Patients With COPD and Cough
NCT01287325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For people with chronic obstructive pulmonary disease (COPD), standard maintenance inhaler treatments consist of inhaled corticosteroids (ICS) and long acting bronchodilators (principal classes include long-acting beta-2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)). Clinical trials indicate that adding ICS to treatment combinations may provide rapid and sustained improvements (1). However, ICS may be associated with adverse effects, notably pneumonia.
There is a need for real-world effectiveness data regarding COPD treatment in order to demonstrate that improvements in lung function translate into reductions in exacerbations, hospitalizations or morbidity.
Objectives and Hypotheses: We hypothesize that ICS containing treatment regimens (including triple therapy - ICS/LABA/LAMA) are more effective at preventing AECOPD than non-ICS containing regimens. The main objective is to assess the impact of ICS therapy on exacerbation outcomes in a COPD population and identify which patient subgroups may achieve the greatest benefit.
Methods:
Study design: Cohort study examining comparative effectiveness
Data Source(s): Clinical Practice Research Datalink (CPRD) GOLD, Hospital Episode Statistics (HES) and Office for National Statistics (ONS) mortality data
Study Population: Patients ≥40 years-old, with a validated diagnosis of COPD registered between the 1st of January 2006 and the 29 February 2016. Eligible patients must have a smoking history, data recorded at least 12 months prior to the study index date and have Up-To-Standard (UTS) data as defined by CPRD.
Exposure(s): ICS containing (LAMA/LABA/ICS and LABA/ICS) regimens and non-ICS containing regimens (LABA/LAMA, LAMA monotherapy).
Outcome(s): Exacerbationsmof COPD, defined using a published algorithm, both GP treated and hospitalised(2), hospitalised pneumonias.
Sample Size Estimations:
A two-sample log-rank test for power indicated that a total of n=2,858 patients (1,429 patients per group) will be required to detect a 15% risk reduction for exacerbation in the triple therapy population compared to the dual-therapy group (comparison which requires the maximum number of patients). This is based on a 60% annual hazard rate for exacerbation in the dual-therapy population and a 51% annual hazard rate for exacerbation in the triple therapy group; assuming power of 90%, alpha=0.05, and a conservative accrual period of one year and a minimum follow-up time of one year.
Statistical Analysis: Descriptive statistics will be used to characterize patients according to baseline demographic, clinical and treatment factors and to study treatment patterns during follow-up.
Analytical statistics will estimate time to exacerbation events per treatment type during the follow-up period. These statistics will include extended Cox regression models, marginal structural models (MSM) and inverse probability weighting (IPW).
Sensitivity analyses will assess follow-up time in incremental periods in order to examine the impact of drug type and drug changes over time. We will also analyse associations between demographic and clinical factors and treatment received.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observation
Cohort of patients with COPD
Standard of Care
Participants will be followed as per local routine primary healthcare practice
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard of Care
Participants will be followed as per local routine primary healthcare practice
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D589BR00039
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.